Integra Bosses Misled on FDA Warning Fix, Shareholder Suit Says

Integra LifeSciences Holdings Corp. brass oversold fixes to its manufacturing practices to meet Food and Drug Administration standards before it shared updates to its compliance improvement program, a shareholder lawsuit said.

Share prices slid multiple times in 2024 as investors learned about issues spurring a shutdown at its Boston plant and the medical device maker’s abilities to meet FDA manufacturing protocol, said the complaint filed in the US District Court for the District of New Jersey Tuesday.

On July 29, Integra reduced its full-year 2024 financial guidance to account for shipping holds and compliance improvement across the company, said the ...